Bray Capital Advisors’s Biogen BIIB Stock Holding History

Bray Capital Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-25	Closed	-$7K	–	271
2022 Q3	$7K	Hold	25	–	–	﹤0.01%	262
2022 Q2	$5K	Hold	25	–	–	﹤0.01%	254
2022 Q1	$5K	Hold	25	–	–	﹤0.01%	260
2021 Q4	$6K	Hold	25	–	–	﹤0.01%	255
2021 Q3	$7K	Hold	25	–	–	﹤0.01%	249
2021 Q2	$9K	Buy	+25	New	+$7.57K	﹤0.01%	242

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bray Capital Advisors's BIIB Position: Q4 2022 in Review

Bray Capital Advisors sold out of Biogen (BIIB) in Q4 2022, closing a stake of 25 shares — an estimated $7K sold.

Bray Capital Advisors first reported a position in BIIB in Q2 2021 and held it in 6 quarters. The position peaked at $9K in Q2 2021. 1,031 funds tracked by Wall St. Rank hold BIIB as of Q4 2022.

Bray Capital Advisors reported no remaining Biogen position as of Q4 2022 after selling out during the quarter.
Bray Capital Advisors sold 25 Biogen shares in Q4 2022, an estimated $7K.
Bray Capital Advisors first reported a position in Biogen in Q2 2021 and held it in 6 quarters.
Bray Capital Advisors's Biogen position peaked at $9K in Q2 2021.
1,031 funds tracked by Wall St. Rank held Biogen as of Q4 2022.

Based on Bray Capital Advisors's 13F filing for Q4 2022, filed 20 Jan 2023.